@Dorisderwent More importantly, if Avacta retain exetecan in AV6207, indirectly it would suggest that it is very much succeeding in AV6103, and it is only a matter of time before the re-rate. I will keep adding at these levels, if the market doesn't understand that yet, great!! DYOR.
@111BEN_111 Spitting in the wind... only comes back to you. Are we there yet? We will get there, that is the only information you need to understand. It is called INVESTING for a reason. It takes time. And noone likes being patient.
@BobDibble8 SP would benefit,short term, from some commercial validation. But I keep saying, if the IP is continuing to expand, and dilution is only in the 10, 20 million range, buying time to allow more mature data to more fully reveal the platform value is fine by me. I just add.
@KirraneJam60371 The study of volcanos shows the the pressure builds slowly over time, like the data, scientific progress and growing relationship with the FDA and industry playmaker. She will blow.
@111BEN_111 Ben, feel you are expecting too much. 1) This AIM. 2) Have you looked at the news recently and all the doom and gloom uncertainty? 3) Nothing has changed with the timelines only things not happening partnership wise as quickly as some would like. We will get there!
@111BEN_111 2/2 Moreover, it may not respond equally in different pathologies, leaving market space for both. You only picked one variable to compare, and that variable is being compared against stage 3 trial versus P1a, so not like for like. Good to get info on M9140. Thanks.
@111BEN_111 1/2 Yes it is a competitor for AV6103, but it's an ADC, rather than PDC, further along the FDA track, but its systemic hit is much greater than AV6103, and with about 25% of responses offering 6.9 months of PFS, it may well offer improvements, but not unbeatable.
@Physio_Ben@DomPosen Not sure this is entirely accurate. The purpose of Phase 1 data is safety, but after 5 years of data, a very close match between pre-clinical and clinical, and now biopsy info, some information about efficacy is entirely possible although clearly incomplete.
@tom_the_bomb__@JStonker@avacta It is not a negative shareholder backdrop. Just some noisy social media types. They are not a majority. Great science becomes future truths.
@neutronicLSE Any deal is not the answer. A good deal is. That requires mature data. And that is on its way. Personally, I am calm and relaxed. I can't personally influence the deal, so I don't fret about what I can't control.
@neutronicLSE 1/2 Everyone assumes that the markets will be rational. Bond rates exploding 'cos countries have been printing money to live beyond there means. Israel runs American foreign policy. The far right are winning seats in Germany. Iran and a few Yemeni rebels control oil flows.